Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "EBITDA"

417 News Found

Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur
News | February 10, 2024

Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur

The 200 bedded hospital owned & operated by Alexis


Zydus Lifesciences Q3 FY24 PAT up 26.8%
News | February 10, 2024

Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.


Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
News | February 09, 2024

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore


IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
News | February 07, 2024

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM


Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24
News | February 01, 2024

Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24

Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth


Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
News | January 23, 2024

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023


Enpro to acquire Advanced Micro Instruments
News | January 02, 2024

Enpro to acquire Advanced Micro Instruments

AMI to become part of Enpro’s Sealing Technologies Segment


IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
News | November 15, 2023

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ


JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
News | November 15, 2023

JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr

Reports revenue growth of 9% to INR 882 crores in Q2 FY24


Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr
News | November 13, 2023

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions